News & Events

News

CYTAVIS’ Aviscumine Improves Survival of Patients with Metastatic Melanoma in a Phase II Trial

Hamburg/Germany, July 13, 2011 – CYTAVIS BioPharma GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced Phase II data demonstrating that its lead compound Aviscumine (CY-503), an immune potentiator, may improve survival of patients with refractory metastatic melanoma (stage IV).

13.07.2011 (10:00) by Prof. Dr. Lentzen

CYTAVIS STARTS RECRUITING PATIENTS FOR PHASE II CLINICAL TRIAL WITH AVISCUMINE (CY-503) IN METASTATIC COLORECTAL CARCINOMA PATIENTS IN AUSTRIA

Hamburg/Germany, March 15, 2011 – CYTAVIS BioPharma today announced the start of patient recruitment for a Phase II trial of its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma in Austria.

15.03.2011 (08:24) by Administrator

CYTAVIS EXPANDS PHASE II CLINICAL TRIAL WITH AVISCUMINE (CY-503) IN METASTATIC COLORECTAL CARCINOMA PATIENTS

Hamburg/Germany, August 25, 2010 – CYTAVIS BioPharma currently is conducting a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma. Already, more than 20 German study centers are participating in the trial.

25.08.2010 (09:00) by Administrator

PHASE II TRIAL WITH AVISCUMINE (CY-503) IN METASTATIC MELANOMA PATIENTS COMPLETED AS SCHEDULED

Hamburg/Germany, August 20, 2010 – CYTAVIS BioPharma today annonced the completion of a phase II trial with its lead compound Aviscumine (CY-503) in patients with refractory metastatic melanoma (stage IV). The study comprising 32 patients was conducted at four German sites (Hauttumorcentrum Charité Berlin Dermatologisches Zentrum Buxtehude / Elbe Klinikum, Haut-Tumor-Zentrum Hannover, Universitäts-Hautklinik Kiel) and is currently being evaluated.

20.08.2010 (09:00) by Administrator

Cytavis Starts Phase II Clinical Trial with Aviscumine in Metastatic Colorectal Carcinoma Patients

Hamburg/Germany, September 14, 2009 – Cytavis GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced the start of a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma (NCT 00932724)

14.09.2009 (10:34) by Administrator

Phase II trial with Aviscumine (CY-503): Metastatic Melanoma

CYTAVIS BioPharma is currently conducting a phase II trial with Aviscumine (CY-503) in patients with metastatic melanoma (stage IV).

01.04.2009 (12:09) by Administrator